<DOC>
	<DOCNO>NCT01493921</DOCNO>
	<brief_summary>Studies SR-T100 gel clinical relevance treatment AK , provide adequate measure outcome skin lesion treatment . In addition high complete response rate ( 90.0 % ) compare conventional therapy , significant result undesirable side effect associate use SR-T100 gel . The result also show approximately 80 % study subject complete response phase II clinical trial conduct Taiwan ; hence , result study model suggest SR-T100 gel offer beneficial therapeutic value treatment AK harmless skin well high tolerance level display majority patient .</brief_summary>
	<brief_title>Efficacy Study &amp; Safety Evaluation SR-T100 Gel Actinic Keratosis Treatment</brief_title>
	<detailed_description>The primary objective study demonstrate clinically significant outcome involve SR-T100 topical gel develop skin lesion AK . Furthermore , evaluation SR-T100 efficacy &amp; tolerability treating AK lesion develop secondary objective clinical study . Patients least two clinically visible , discrete , non-hyperkeratotic , non-hypertrophic AK lesion arm , shoulder , chest , face scalp least one lesion great equal 4mm diameter within total 25 cm square contiguous non-contiguous treatment expect enrol . Candidate pool divide two group random assignment treatment group placebo group . This randomization scheme generate biostatistics produce computer software program incorporate standard procedure generate random probability . Study procedure include laboratory testing , analytical reading well clinical assessment practice treatment efficacy safety evaluation .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Male female 20 year age patient least two clinically visible , discrete , non hyperkeratotic , hypertrophic AK lesion locate within 25 cm square contiguous non contiguous treatment area include arm , shoulder , chest , face scalp . Patient least one histological confirm actinic keratosis lesion great equal 4 mm diameter within select treatment area . 1 . Patient dermatological disease condition , atopic dermatitis , basal cell carcinoma , eczema , psoriasis , rosacea , squamous cell carcinoma , melanoma , possible confound skin condition treatment surround area within 5cm distance treatment area . 2 . Patient use follow treatment within 4 week prior study treatment initiation immunomodulators immunosuppressive therapy , interferon cytotoxic drug . 3 . Patient treat topical 5 FU , diclofenac gel , imiquimod , corticosteroid , retinoids , masoprocol treatment area within 4 week prior study treatment initiation . 4 . Patient receive cryodestruction , chemodestruction , curettage , photodynamic therapy , surgical excision treatment area within 4 week prior study treatment initiation . 5 . Patient receive follow treatment treatment area 6 month study treatment initiation begin , psoralen plus UVA therapy , UVB therapy , laser abrasion , dermabrasion chemical peel . 6 . Patient know hypersensitive study medication . 7 . Female pregnant , breast fed considers become pregnant study . 8 . Patient use investigational drug within past 30 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>SR-T100 Clinical treatment Actinic Keratosis</keyword>
	<keyword>Actinic keratosis skin lesion treatment SR-T100 gel</keyword>
	<keyword>Skin lesion treatment SR-T100 gel</keyword>
	<keyword>SR-T100 gel treatment skin lesion</keyword>
	<keyword>Clinical efficacy study SR-T100 gel</keyword>
</DOC>